John Mark O'mahony - Net Worth and Insider Trading

John Mark O'mahony Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Mark O'mahony owns 1 companies in total, including Leap Therapeutics Inc (LPTX) .

Click here to see the complete history of John Mark O'mahony’s form 4 insider trades.

Insider Ownership Summary of John Mark O'mahony

Ticker Comapny Transaction Date Type of Owner
LPTX Leap Therapeutics Inc 2020-04-01 Chief Manufacturing Officer

John Mark O'mahony Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

John Mark O'mahony Ownership Network

Ownership Network List of John Mark O'mahony

No Data

Ownership Network Relation of John Mark O'mahony

Insider Network Chart

John Mark O'mahony Owned Company Details

What does Leap Therapeutics Inc do?

Who are the key executives at Leap Therapeutics Inc?

John Mark O'mahony is the Chief Manufacturing Officer of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , 10 percent owner Beigene, Ltd. , and VP & Head of Reg Affairs/Qual Christine Granfield .

Leap Therapeutics Inc (LPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Leap Therapeutics Inc Insider Transactions

No Available Data

John Mark O'mahony Mailing Address

Above is the net worth, insider trading, and ownership report for John Mark O'mahony. You might contact John Mark O'mahony via mailing address: C/o Leap Therapeutics, Inc., 47 Thorndike Street, Suite B1-1, Cambridge Ma 02141.

Discussions on John Mark O'mahony

No discussions yet.